Literature DB >> 2456781

Selective strand scission by intercalating drugs at DNA bulges.

L D Williams1, I H Goldberg.   

Abstract

A bulge is an extra, unpaired nucleotide on one strand of a DNA double helix. This paper describes bulge-specific strand scission by the DNA intercalating/cleaving drugs neocarzinostatin chromophore (NCS-C), bleomycin (BLM), and methidiumpropyl-EDTA (MPE). For this study we have constructed a series of 5'-32P end labeled oligonucleotide duplexes that are identical except for the location of a bulge. In each successive duplex of the series, a bulge has been shifted stepwise up (from 5' to 3') one strand of the duplex. Similarly, in each successive duplex of the series, sites of bulge-specific scission and protection were observed to shift in a stepwise manner. The results show that throughout the series of bulged duplexes NCS-C causes specific scission at a site near a bulge, BLM causes specific scission at a site near a bulge, and MPE-Fe(II) causes specific scission centered around the bulge. In some sequences, NCS-C and BLM each cause bulge-specific scission at second sites. Further, bulged DNA shows sites of protection from NCS-C and BLM scission. The results are consistent with a model of bulged DNA with (1) a high-stability intercalation site at the bulge, (2) in some sequences, a second high-stability intercalation site adjacent to the first site, and (3) two sites of relatively unstable intercalation that flank the two stable intercalation sites. On the basis of our results, we propose a new model of the BLM/DNA complex with the site of intercalation on the 3' side (not in the center) of the dinucleotide that determines BLM binding specificity.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2456781     DOI: 10.1021/bi00408a051

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

1.  Noncovalent DNA binding drives DNA alkylation by leinamycin: evidence that the Z,E-5-(thiazol-4-yl)-penta-2,4-dienone moiety of the natural product serves as an atypical DNA intercalator.

Authors:  Mostafa I Fekry; Jozsef Szekely; Sanjay Dutta; Leonid Breydo; Hong Zang; Kent S Gates
Journal:  J Am Chem Soc       Date:  2011-10-18       Impact factor: 15.419

2.  A novel assay for drug-DNA binding mode, affinity, and exclusion number: scanning force microscopy.

Authors:  J E Coury; L McFail-Isom; L D Williams; L A Bottomley
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

3.  Biochemical and biophysical studies on the folding of the core region of the origin of replication of bacteriophage M13.

Authors:  A van Belkum; M J Blommers; H van den Elst; J H van Boom; C W Hilbers
Journal:  Nucleic Acids Res       Date:  1990-08-25       Impact factor: 16.971

4.  Site-specific cleavage of RNA by Fe(II).bleomycin.

Authors:  B J Carter; E de Vroom; E C Long; G A van der Marel; J H van Boom; S M Hecht
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

5.  Fe.bleomycin as a probe of RNA conformation.

Authors:  C E Holmes; A T Abraham; S M Hecht; C Florentz; R Giegé
Journal:  Nucleic Acids Res       Date:  1996-09-01       Impact factor: 16.971

6.  The ensemble reactions of hydroxyl radical exhibit no specificity for primary or secondary structure of DNA.

Authors:  S E Rokita; L Romero-Fredes
Journal:  Nucleic Acids Res       Date:  1992-06-25       Impact factor: 16.971

7.  Specific binding of o-phenanthroline at a DNA structural lesion.

Authors:  L D Williams; J Thivierge; I H Goldberg
Journal:  Nucleic Acids Res       Date:  1988-12-23       Impact factor: 16.971

8.  PARP3 is a promoter of chromosomal rearrangements and limits G4 DNA.

Authors:  Tovah A Day; Jacob V Layer; J Patrick Cleary; Srijoy Guha; Kristen E Stevenson; Trevor Tivey; Sunhee Kim; Anna C Schinzel; Francesca Izzo; John Doench; David E Root; William C Hahn; Brendan D Price; David M Weinstock
Journal:  Nat Commun       Date:  2017-04-27       Impact factor: 14.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.